Liquid Biopsy Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

  • Product Code:
    RP-ID-10078029
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    120
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Liquid Biopsy Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Liquid biopsy is a minimally or non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. These tests have considerable potential for early detection of cancer, treatment and recurrence monitoring, detection of genetic abnormalities in fetus, and graft rejection in transplantation patients. According to the estimation of National Cancer Institute, in the US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths are estimated in 2016. While in Europe 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.
The liquid biopsy market is booming due to the rising prevalence of cancer globally, advanced maternal age leading to growing chromosomal aberrations, and the increasing preference of non-invasive liquid biopsy tests over invasive tissue biopsy. The lack of sensitivity and specificity of liquid biopsy tests, high cost of the test with fewer reimbursement facilities, and the lack of trained professionals are some of the factors hampering the market growth. The markets in emerging countries are expected to grow at a rapid pace during the forecast period due to the increasing disease prevalence, healthcare awareness, and healthcare spending.
Market Analysis: The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017–2023. The market is analyzed based on three segments, namely biomarker type, sample type, application, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the liquid biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.
Biomarker Type Analysis: The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment is the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology.
Sample Type Analysis: The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupies the major market share in 2016 since most of the tests currently available in the market are blood-based tests.
Application Analysis: The global liquid biopsy market by application is segmented into cancer and non-cancer applications. Cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecasted period. Cancer application is further segmented by cancer indication and clinical application.
End-users Analysis: The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.
Key Players: Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.
Competitive Analysis: Currently, cancer tests dominate the global liquid biopsy market. A lot of new players are concentrating on this market to provide ground-breaking test with high sensitivity, specificity, and less turnaround time. Major market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, the major players are launching innovative tests to have an upper hand in the market. For instance, in September 2017, Biocept launched Liquid Biopsy test for NRAS mutations.
Benefits: The report provides complete details about the usage and adoption rate of liquid biopsy tests in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding their business in this market.
Key Stakeholders:


Table of Contents
1 INDUSTRY OUTLOOK 9
1.1 Industry overview 9
1.2 Total addressable market 9
1.3 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Importance of Cell-Free DNA testing 13
3.3 Complications of Cell-Free DNA testing 13
3.4 Segmented Addressable Market (SAM) 14
3.5 Industry Trends 14
3.6 Related Markets 16
3.6.1 Liquid biopsy market 16
3.6.2 Transplantation Diagnostics Market 16
4 Market Outlook 16
4.1 Overview 16
4.2 Regulatory framework 17
4.3 Funding scenario 18
4.4 Market segmentation 19
4.5 PEST Analysis 20
4.6 Porter 5(Five) Forces 21
5 Market Characteristics 22
5.1 DRO – Global Cell-free DNA testing Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies 22
5.1.1.2 Rising number of cancers 23
5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis 23
5.1.2 Opportunities 24
5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries 24
5.1.2.2 Increase in mergers & acquisitions 24
5.1.3 Restraints 24
5.1.3.1 High test cost with less reimbursement facilities 24
5.1.3.2 Ethical issues 25
5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing 25
6 Test Types: Market Size and Analysis 28
6.1 Overview 28
6.2 Non-invasive prenatal tests (NIPT) 29
6.3 Circulating tumour DNA tests 30
6.4 Donor-derived cell free DNA tests 32
7 Application: Market Size and Analysis 33
7.1 Overview 33
7.2 Prenatal testing 35
7.3 Cancer 35
7.4 Transplantation diagnostics 36
8 Regions: Market Size and Analysis 37
8.1 Overview 37
8.2 North America 38
8.2.1 Overview 38
8.2.2 United states 38
8.2.3 Canada 39
8.3 Europe 39
8.3.1 Overview 39
8.3.2 United Kingdom 40
8.3.3 Germany 41
8.3.4 France 41
8.3.5 Spain 41
8.4 APAC 42
8.4.1 Overview 42
8.4.2 India 42
8.4.3 China 43
8.5 Rest of the World 43
8.5.1 Overview 43
8.5.2 Brazil 44
8.5.3 Middle East 44
9 Competitive Landscape 45
9.1 Overview 45
10 Vendor Profiles 48
10.1 Natera, Inc. 48
10.1.1 Overview 48
10.1.2 Natera Inc.: Product offerings 48
10.1.3 NATERA, INC.: Recent Developments 49
10.1.4 Geographic Presence 52
10.1.5 Business Focus 52
10.1.6 SWOT Analysis 53
10.1.7 Business Strategy 53
10.2 Laboratory Corporation of America Holdings (LABCORP) 54
10.2.1 Overview 54
10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings 55
10.2.3 Laboratory Corporation Of America Holdings: Recent Developments 56
10.2.4 Business Unit 58
10.2.5 Geographic Presence 58
10.2.6 Business Focus 59
10.2.7 SWOT Analysis 59
10.2.8 Business Strategy 60
10.3 Illumina, Inc., 61
10.3.1 Overview 61
10.3.2 Illumina, INC: Product offerings 61
10.3.3 Illumina, INC: Recent Developments 62
10.3.4 Geographic Presence 66
10.3.5 Business Focus 66
10.3.6 SWOT Analysis 67
10.3.7 Business Strategy 67
10.4 BEIJING GENOMICS INSTITUTE 68
10.4.1 Overview 68
10.4.2 Beijing Genomics Institute: Product offerings 68
10.4.3 Beijing Genomics Institute: Recent Developments 69
10.4.4 Business Focus 69
10.4.5 SWOT Analysis 69
10.4.6 Business Strategy 70
10.5 F.Hoffmann-La Roche Ltd 71
10.5.1 Overview 71
10.5.2 F. Hoffmann-la Roche: Product Offerings 71
10.5.3 F. Hoffmann-la roche.: Recent Developments 72
10.5.4 Business Unit 75
10.5.5 Geographic Presence 76
10.5.6 Business Focus 76
10.5.7 SWOT Analysis 77
10.5.8 Business Strategy 77
Companies to Watch For 78
10.6 CareDx, Inc 78
10.6.1 Overview 78
10.6.2 caredx: Recent Developments 79
10.7 LifeCodexx AG 80
10.7.1 Overview 80
10.7.2 LifeCodexx AG: Recent Developments 80
10.8 Biocept, Inc. 81
10.8.1 Overview 81
10.8.2 Biocept, Inc.: Recent Developments 82
10.9 Quest Diagnostics 84
10.9.1 Overview 84
10.9.2 Quest Diagnostics: Recent Developments 85
10.10 Guardant Health 87
10.10.1 Overview 87
10.10.2 Guardant Health: Recent Developments 87
10.11 Inivata Limited 89
10.11.1 Overview 89
10.11.2 Inivata Limited: Recent Developments 89
10.12 Personal Genome Diagnostics 90
10.12.1 Overview 90
10.12.2 Personal Genome Diagnostics: Recent Developments 91
10.13 Trovagene 91
10.13.1 Overview 91
10.13.2 Trovagene, Inc.: Recent Developments 92
Annexure 94
Abbreviations 94


Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports